Skip to content

Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model

Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05589012
Acronym
ZITOPEx
Enrollment
0
Registered
2022-10-21
Start date
2023-11-01
Completion date
2024-04-01
Last updated
2026-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zika Virus Infection

Keywords

trophoblast, placenta

Brief summary

Prospective, non-interventional study carried out after culturing placental trophoblastic tissue ex vivo and infection with Zika and Tonate

Detailed description

The analysis will relate for each virus studied + control + favipiravir to 1 placenta in the 1st trimester and 1 placenta at term. 2 experiments per virus will be planned.

Interventions

BIOLOGICALCell line and virus

C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.

BIOLOGICALInfection of human placental culture explants

Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots. Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air.

BIOLOGICALDetermination of viral load in tissues by qRT-PCR

The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions. Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV.

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient over 18 years old * Singleton pregnancy of normal course, at term, birth by caesarean section OR * Trophoblast from Voluntary Termination of Pregnancy (IVG), after endo-uterine aspiration

Exclusion criteria

* Need for pathological, genetic or bacteriological examination of the placenta * Multiple pregnancy * HBV+ (Hepatitis B positive), HCV+ (Hepatitis C positive) , known CMV seroconversion during pregnancy (CytoMégaloVirus) * Immunosuppression (drugs, corticosteroids, etc.) * Diabetes * Pre eclampsia * Intrauterine growth retardation (IUGR), * Vascular or placental pathology. * Refusal to participate * Patient under guardianship / curatorship / security measure * Patient under AME (state medical aid)

Design outcomes

Primary

MeasureTime frameDescription
To assess the replication potential of TONV and ZIKV after placenta infection ex vivo.inclusionDetermine the viral load (RT-qtPCR) of TONV and ZIKV after placenta infection, ex vivo in RNA copies/mL

Secondary

MeasureTime frameDescription
Validate the ex vivo placental model for TONV.InclusionAnalysis of viral load in placental explants for TONV in RNA copies/mL
Compare viral infection of the placenta at different terms of pregnancy (first trimester and term).first trimesterAnalysis of the viral load according to the term in RNA copies/mL
Compare the placental infection of TONV versus ZIKV.inclusionAnalysis of viral load depending on the virus (ZIKV vs TONV) in RNA copies/mL
Highlight the cellular targets of TONV.inclusionHistological analysis and labeling of TONV cells in RNA copies/mL

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 13, 2026